BACKGROUND: Mast cell tumors (MCT) are common cutaneous tumors in dogs and when not amenable to surgical excision can present a therapeutic challenge. New treatment protocols for unresectable MCT are needed. HYPOTHESIS: The combination of toceranib, prednisone, and hypofractionated radiation treatment (RT) will be well tolerated and efficacious. ANIMALS: Seventeen client-owned dogs with measurable MCT amenable to RT. METHODS: Prospective clinical trial. All dogs received prednisone, omeprazole, diphenhydramine, and toceranib. Toceranib was administered for 1 week before initiating RT, consisting of 24 Gy delivered in 3 or 4 fractions. RESULTS: On an intent-to-treat basis, the overall response rate was 76.4%, with 58.8% of dogs achieving a complete response and 17.6% a partial response. The median time to best response was 32 days, and the median progression-free interval was 316 days. The overall median survival time was not reached with a median follow-up of 374 days. The most common toxicoses were gastrointestinal and hepatic. CONCLUSIONS AND CLINICAL IMPORTANCE: The combination of hypofractionated RT, toceranib, and prednisone was tolerated and efficacious in the majority of dogs. Response rates and durations were higher than those reported for toceranib as a single-agent treatment for MCT. This combination is a viable treatment option for unresectable MCT.
BACKGROUND:Mast cell tumors (MCT) are common cutaneous tumors in dogs and when not amenable to surgical excision can present a therapeutic challenge. New treatment protocols for unresectable MCT are needed. HYPOTHESIS: The combination of toceranib, prednisone, and hypofractionated radiation treatment (RT) will be well tolerated and efficacious. ANIMALS: Seventeen client-owned dogs with measurable MCT amenable to RT. METHODS: Prospective clinical trial. All dogs received prednisone, omeprazole, diphenhydramine, and toceranib. Toceranib was administered for 1 week before initiating RT, consisting of 24 Gy delivered in 3 or 4 fractions. RESULTS: On an intent-to-treat basis, the overall response rate was 76.4%, with 58.8% of dogs achieving a complete response and 17.6% a partial response. The median time to best response was 32 days, and the median progression-free interval was 316 days. The overall median survival time was not reached with a median follow-up of 374 days. The most common toxicoses were gastrointestinal and hepatic. CONCLUSIONS AND CLINICAL IMPORTANCE: The combination of hypofractionated RT, toceranib, and prednisone was tolerated and efficacious in the majority of dogs. Response rates and durations were higher than those reported for toceranib as a single-agent treatment for MCT. This combination is a viable treatment option for unresectable MCT.
Authors: Joshua D Webster; Vilma Yuzbasiyan-Gurkan; John B Kaneene; RoseAnn Miller; James H Resau; Matti Kiupel Journal: Neoplasia Date: 2006-02 Impact factor: 5.715
Authors: Johanna E Todd; Sandra M Nguyen; Joanna White; Veronika Langova; Penelope M Thomas; Sophia Tzannes Journal: Can Vet J Date: 2021-12 Impact factor: 1.008
Authors: J H Burton; R O Venable; D M Vail; L E Williams; C A Clifford; S M Axiak-Bechtel; A C Avery; D H Thamm Journal: J Vet Intern Med Date: 2015-06-25 Impact factor: 3.333
Authors: Michael Willmann; Emir Hadzijusufovic; Olivier Hermine; Mauro Dacasto; Laura Marconato; Karin Bauer; Barbara Peter; Susanne Gamperl; Gregor Eisenwort; Erika Jensen-Jarolim; Mathias Müller; Michel Arock; David M Vail; Peter Valent Journal: Vet Comp Oncol Date: 2018-09-24 Impact factor: 2.613
Authors: Andrigo Barboza de Nardi; Rodrigo Dos Santos Horta; Carlos Eduardo Fonseca-Alves; Felipe Noleto de Paiva; Laís Calazans Menescal Linhares; Bruna Fernanda Firmo; Felipe Augusto Ruiz Sueiro; Krishna Duro de Oliveira; Silvia Vanessa Lourenço; Ricardo De Francisco Strefezzi; Carlos Henrique Maciel Brunner; Marcelo Monte Mor Rangel; Paulo Cesar Jark; Jorge Luiz Costa Castro; Rodrigo Ubukata; Karen Batschinski; Renata Afonso Sobral; Natália Oyafuso da Cruz; Adriana Tomoko Nishiya; Simone Crestoni Fernandes; Simone Carvalho Dos Santos Cunha; Daniel Guimarães Gerardi; Guilherme Sellera Godoy Challoub; Luiz Roberto Biondi; Renee Laufer-Amorim; Paulo Ricardo de Oliveira Paes; Gleidice Eunice Lavalle; Rafael Ricardo Huppes; Fabrizio Grandi; Carmen Helena de Carvalho Vasconcellos; Denner Santos Dos Anjos; Ângela Cristina Malheiros Luzo; Julia Maria Matera; Miluse Vozdova; Maria Lucia Zaidan Dagli Journal: Cells Date: 2022-02-10 Impact factor: 6.600
Authors: Charles H C Halsey; Daniel L Gustafson; Barbara J Rose; Amber Wolf-Ringwall; Robert C Burnett; Dawn L Duval; Anne C Avery; Douglas H Thamm Journal: BMC Vet Res Date: 2014-05-06 Impact factor: 2.741
Authors: K M Weishaar; E J Ehrhart; A C Avery; J B Charles; R E Elmslie; D M Vail; C A London; C A Clifford; J C Eickhoff; D H Thamm Journal: J Vet Intern Med Date: 2017-11-30 Impact factor: 3.333